Major clinical research advances in gynecologic cancer in 2011

Journal of Gynecologic Oncology

Volumn 23, Issue 1, 2012, Pages 53-64

  Suh, Dong Hoon ^a   Kim, Kidong ^b   Kim, Jae Weon ^a  

^a Seoul National University College of Medicine   (South Korea)

^b Seoul National University Bundang Hospital   (South Korea)

Author keywords

Breast cancer; Comprehensive genomic analyses; Gynecologic oncology; Human papillomavirus vaccines; Poly (adpribose) polymerase inhibitors

Indexed keywords

AROMATASE INHIBITOR; BEVACIZUMAB; CARBOPLATIN; CISPLATIN; DOXORUBICIN; ERIBULIN; EXEMESTANE; GEMCITABINE; GONADORELIN DERIVATIVE; GSK 2141795; INIPARIB; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; OLAPARIB; PACLITAXEL; PLACEBO; TERBUTALINE SULFATE; TRIPTORELIN; UNCLASSIFIED DRUG; WART VIRUS VACCINE;

ADD ON THERAPY; ADJUVANT THERAPY; ADVANCED CANCER; ANEMIA; ARTICLE; ASTHENIA; BREAST CANCER; BREAST METASTASIS; CANCER CHEMOTHERAPY; CANCER PREVENTION; CANCER PROGNOSIS; CANCER RESEARCH; CANCER SCREENING; CANCER SURVIVAL; CLINICAL RESEARCH; DRUG WITHDRAWAL; EARLY MENOPAUSE; ENDOMETRIUM CANCER; FATIGUE; GYNECOLOGIC CANCER; HUMAN; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVARY CANCER; PAPILLOMA VIRUS; PREMENOPAUSE; QUALITY OF LIFE; SENTINEL LYMPH NODE BIOPSY; UNSPECIFIED SIDE EFFECT; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; UTERINE TUBE CARCINOMA; VOMITING;

EID: 84863275781     PISSN: 20050380     EISSN: 20050399     Source Type: Journal    
DOI: 10.3802/jgo.2012.23.1.53     Document Type: Article

References (68)

1. Suh DH, Kim JW, Kim K, Kang SB. Major clinical research advances in gynecologic cancer in 2010. J Gynecol Oncol 2010;21:209-18.
2. Cancer Genome Atlas Research Network. Integrated ge nomic analyses of ovarian carcinoma. Nature 2011;474:609-15.
3. van Dam GM, Themelis G, Crane LM, Harlaar NJ, Pleijhuis RG, Kelder W, et al. Intraoperative tumor-specific fluore scence imaging in ovarian cancer by folate receptor-α targeting: first in-human results. Nat Med 2011;17:1315-9.
4. Koppe MJ, Boerman OC, Oyen WJ, Bleichrodt RP. Perito neal carcinomatosis of colorectal origin: incidence and current treatment strategies. Ann Surg 2006;243:212-22.
5. Burger RA, Brady MF, Rhee J, Sovak MA, Nguyen H, Book man MA. Independent radiologic review of GOG218, a phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian (EOC), primary peri toneal (PPC), or fallopian tube cancer (FTC). J Clin Oncol 2011;29(suppl): abstract 5023.
6. Kristensen G, Perren T, Qian W, Pfisterer J, Ledermann JA, Joly F, et al. Result of interim anlysis of overall survival in the GCIG ICON 7 phase III randomized trial of bevacizumab in women with newly diagnosed ovarian cancer. J Clin Oncol 2011;29(suppl): abstract LBA5006.
7. Gaitskell K, Martinek I, Bryant A, Kehoe S, Nicum S, Morrison J. Angiogenesis inhibitors for the treatment of ovarian cancer. Cochrane Database Syst Rev 2011;9:CD007930.
8. Aghajanian C, Finkler NJ, Rutherford T, Smith DA, Yi J, Parmar H, et al. OCEANS: A randomized, double-blinded, placebo-controlled phase III trial of chemotherapy with or without bevacizumab (BEV) in patients with platinum- sensitive recurrent epithelial ovarian (EOC), primary peri toneal (PPC), or fallopian tube cancer (FTC). J Clin Oncol 2011;29(suppl): abstract LBA5007.
9. Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richar dson TB, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005;434: 917-21.
10. Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005;434:913-7.
11. Fong PC, Yap TA, Boss DS, Carden CP, Mergui-Roelvink M, Gourley C, et al. Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J Clin Oncol 2010; 28:2512-9.
12. Audeh MW, Carmichael J, Penson RT, Friedlander M, Powell B, Bell-McGuinn KM, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 2010;376:245-51.
13. Telli ML. PARP inhibitors in cancer: moving beyond BRCA. Lancet Oncol 2011;12:827-8.
14. Gelmon KA, Tischkowitz M, Mackay H, Swenerton K, Robi doux A, Tonkin K, et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carci noma or triple-negative breast cancer: a phase 2, multi centre, open-label, non-randomised study. Lancet Oncol 2011;12:852-61.
15. Ledermann JA, Harter P, Gourley C, Friedlander M, Vergote IB, Rustin GJ, et al. Phase II randomized placebo-controlled study of olaparib (AZD2281) in patients with platinum-sensitive relapsed serous ovarian cancer (PSR SOC). J Clin Oncol 2011;29(suppl):abstr 5003.
16. Penson RT, Whalen C, Lasonde B, Krasner CN, Konstantinopoulos P, Stallings TE, et al. A phase II trial of iniparib (BSI-201) in combination with gemcitabine/carboplatin (GC) in patients with platinum-sensitive recurrent ovarian cancer. J Clin Oncol 2011;29(suppl):abstr 5004.
17. Birrer MJ, Konstantinopoulos P, Penson RT, Roche M, Ambrosio A, Stallings TE, et al. A phase II trial of iniparib (BSI- 201) in combination with gemcitabine/carboplatin (GC) in patients with platinum-resistant recurrent ovarian cancer. J Clin Oncol 2011;29(suppl):abstr 5005.
18. Gungor H, Stronach E, Curry E, Saleem A, Agarwal R, Blagden S, et al. Mutation and protein expression biomarkers corrleate with response to AKT inhibition in a phase I trial of the oral pan AKT inhibitor GSK2141795 (GSK795) in patients (pts) with platinum resistant ovarian cancer. 2011 European Multi disciplinary Cancer Congress; 2011 Sep 23-27; Stockholm, Sweden. Abstract LBA24.
19. National Comprehensive Cancer Network. NCCN clinical practice guidelines. Oncology: genetic/familial high-risk assessment: breast and ovarian. Ver. 1.2011 [Internet]. Fort Washington, PA: National Comprehensive Cancer Network; 2011 [cited 2011 Nov 30]. Available from: http://www.nccn.org/professionals/physician_gls/f_guidelines. asp.
20. Berek JS, Chalas E, Edelson M, Moore DH, Burke WM, Cliby WA, et al. Prophylactic and risk-reducing bilateral salpingo-oophorectomy: recommendations based on risk of ovarian cancer. Obstet Gynecol 2010;116:733-43.
21. Rebbeck TR, Lynch HT, Neuhausen SL, Narod SA, Van't Veer L, Garber JE, et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 2002;346:1616-22.
22. Westin SN, Sun CC, Lu KH, Schmeler KM, Soliman PT, Lacour RA, et al. Satisfaction with ovarian carcinoma risk-reduction strategies among women at high risk for breast and ovarian carcinoma. Cancer 2011;117:2659-67.
23. Chapman JS, Powell CB, McLennan J, Crawford B, Mak J, Stewart N, et al. Surveillance of survivors: follow-up after risk-reducing salpingo-oophorectomy in BRCA 1/2 muta tion carriers. Gynecol Oncol 2011;122:339-43.
24. Domchek SM, Friebel T, Neuhausen SL, Lynch HT, Singer CF, Eeles RA, et al. Is hotmone replacement therapy (HRT) following risk-reducing salpingo-oophorectomy (RRSO) in BRCA (B1)-and BRCA2 (B2)-mutation carriers associated with an increased risk of breast cancer? J Clin Oncol 2011; 29(suppl):abstr 1501.
25. Challberg J, Ashcroft L, Lalloo F, Eckersley B, Clayton R, Hopwood P, et al. Menopausal symptoms and bone health in women undertaking risk reducing bilateral salpingo-oophorectomy: significant bone health issues in those not taking HRT. Br J Cancer 2011;105:22-7.
26. Cohen JV, Chiel L, Boghossian L, Jones M, Stopfer JE, Powers J, et al. Non-cancer endpoints in BRCA1/2 carriers after risk-reducing salpingo-oophorectomy. Fam Cancer 2011 Sep 6 [Epub]. http://dx.doi.org/10.1007/s10689-011-9480-8.
27. Buys SS, Partridge E, Black A, Johnson CC, Lamerato L, Isaacs C, et al. Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Scree ning Randomized Controlled Trial. JAMA 2011;305:2295-303.
28. Menon U, Gentry-Maharaj A, Hallett R, Ryan A, Burnell M, Sharma A, et al. Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncol 2009;10:327-40.
29. Moore RG, McMeekin DS, Brown AK, DiSilvestro P, Miller MC, Allard WJ, et al. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in pa tients with a pelvic mass. Gynecol Oncol 2009;112:40-6.
30. Van Gorp T, Cadron I, Despierre E, Daemen A, Leunen K, Amant F, et al. HE4 and CA125 as a diagnostic test in ova rian cancer: prospective validation of the Risk of Ovarian Malignancy Algorithm. Br J Cancer 2011;104:863-70.
31. Bandiera E, Romani C, Specchia C, Zanotti L, Galli C, Ruggeri G, et al. Serum human epididymis protein 4 and risk for ovarian malignancy algorithm as new diagnostic and prognostic tools for epithelial ovarian cancer management. Cancer Epidemiol Biomarkers Prev 2011;20:2496-506.
32. Lehtinen M, Paavonen J, Wheeler CM, Jaisamrarn U, Garland SM, Castellsague X, et al. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervi cal intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 2011 Nov 8 [Epub]. http://dx.doi.org/10.1016/ S1470-2045(11)70286-8.
33. Wheeler CM, Castellsague X, Garland SM, Szarewski A, Paavonen J, Naud P, et al. Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double- blind PATRICIA trial. Lancet Oncol 2011 Nov 8 [Epub]. http://dx.doi.org/10.1016/S1470-2045(11)70287-X.
34. Kreimer AR, Rodriguez AC, Hildesheim A, Herrero R, Porras C, Schiffman M, et al. Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine. J Natl Cancer Inst 2011;103:1444-51.
35. Brotherton JM, Fridman M, May CL, Chappell G, Saville AM, Gertig DM. Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study. Lancet 2011;377:2085-92.
36. Giuliano AR, Palefsky JM, Goldstone S, Moreira ED Jr, Penny ME, Aranda C, et al. Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males. N Engl J Med 2011;364:401-11.
37. Wright TC Jr, Massad LS, Dunton CJ, Spitzer M, Wilkinson EJ, Solomon D, et al. 2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests. Am J Obstet Gynecol 2007;197:346-55.
38. Saraiya M, Berkowitz Z, Yabroff KR, Wideroff L, Kobrin S, Benard V. Cervical cancer screening with both human pa pillomavirus and Papanicolaou testing vs Papanicolaou testing alone: what screening intervals are physicians re commending? Arch Intern Med 2010;170:977-85.
39. Katki HA, Kinney WK, Fetterman B, Lorey T, Poitras NE, Cheung L, et al. Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice. Lancet Oncol 2011;12:663-72.
40. Szarewski A, Cadman L, Mesher D, Austin J, Ashdown-Barr L, Edwards R, et al. HPV self-sampling as an alternative strategy in non-attenders for cervical screening - a rando mized controlled trial. Br J Cancer 2011;104:915-20.
41. Lazcano-Ponce E, Lorincz AT, Cruz-Valdez A, Salmeron J, Uribe P, Velasco-Mondragon E, et al. Self-collection of vaginal specimens for human papillomavirus testing in cervical cancer prevention (MARCH): a community-based randomised controlled trial. Lancet 2011;378:1868-73.
42. Wikstrom I, Lindell M, Sanner K, Wilander E. Self-sampling and HPV testing or ordinary Pap-smear in women not regularly attending screening: a randomized study. Br J Cancer 2011;105:337-9.
43. Lindell M, Sanner K, Wikstrom I, Wilander E. Self-sampling of vaginal fluid and high-risk human papillomavirus testing in women aged 50 years or older not attending Papanicolaou smear screening. BJOG 2012;119:245-8.
44. Rose PG, Bundy BN, Watkins EB, Thigpen JT, Deppe G, Maiman MA, et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med 1999;340:1144-53.
45. Duenas-Gonzalez A, Zarba JJ, Patel F, Alcedo JC, Beslija S, Casanova L, et al. Phase III, open-label, randomized study comparing concurrent gemcitabine plus cisplatin and ra diation followed by adjuvant gemcitabine and cisplatin versus concurrent cisplatin and radiation in patients with stage IIB to IVA carcinoma of the cervix. J Clin Oncol 2011; 29:1678-85.
46. Rose PG. Combination therapy: New treatment paradigm for locally advanced cervical cancer? Nat Rev Clin Oncol 2011;8:388-90.
47. Ryu SY, Lee WM, Kim K, Park SI, Kim BJ, Kim MH, et al. Randomized clinical trial of weekly vs. triweekly cisplatin-based chemotherapy concurrent with radiotherapy in the treatment of locally advanced cervical cancer. Int J Radiat Oncol Biol Phys 2011;81:e577-81.
48. ASTEC study group, Kitchener H, Swart AM, Qian Q, Amos C, Parmar MK. Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study. Lancet 2009;373:125-36.
49. Benedetti Panici P, Basile S, Maneschi F, Alberto Lissoni A, Signorelli M, Scambia G, et al. Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial. J Natl Cancer Inst 2008;100:1707-16.
50. May K, Bryant A, Dickinson HO, Kehoe S, Morrison J. Lym-phadenectomy for the management of endometrial cancer. Cochrane Database Syst Rev 2010;(1):CD007585.
51. Selman TJ, Mann CH, Zamora J, Khan KS. A systematic review of tests for lymph node status in primary endometrial cancer. BMC Womens Health 2008;8:8.
52. Ballester M, Dubernard G, Lecuru F, Heitz D, Mathevet P, Marret H, et al. Detection rate and diagnostic accuracy of sentinel-node biopsy in early stage endometrial cancer: a prospective multicentre study (SENTI-ENDO). Lancet Oncol 2011;12:469-76.
53. Bremond A, Bataillard A, Thomas L, Achard JL, Fervers B, Fondrinier E, et al. Standards, Options and Recommen dations 2000 for the management of patients with endometrial cancer (non-metastatic)(abridged report). Gynecol Obstet Fertil 2002;30:902-16.
54. Petru E, Luck HJ, Stuart G, Gaffney D, Millan D, Vergote I, et al. Gynecologic Cancer Intergroup (GCIG) proposals for changes of the current FIGO staging system. Eur J Obstet Gynecol Reprod Biol 2009;143:69-74.
55. Kitchener HC. Sentinel-node biopsy in endometrial cancer: a win-win scenario? Lancet Oncol 2011;12:413-4.
56. Goss PE, Ingle JN, Ales-Martinez JE, Cheung AM, Chlebowski RT, Wactawski-Wende J, et al. Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med 2011; 364:2381-91.
57. Lippman SM. The dilemma and promise of cancer chemoprevention. Nat Clin Pract Oncol 2006;3:523.
58. Ropka ME, Keim J, Philbrick JT. Patient decisions about breast cancer chemoprevention: a systematic review and meta-analysis. J Clin Oncol 2010;28:3090-5.
59. Visvanathan K, Chlebowski RT, Hurley P, Col NF, Ropka M, Collyar D, et al. American society of clinical oncology clini cal practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. J Clin Oncol 2009;27:3235-58.
60. Chlebowski RT, Col N, Winer EP, Collyar DE, Cummings SR, Vogel VG 3rd, et al. American Society of Clinical Oncology technology assessment of pharmacologic interventions for breast cancer risk reduction including tamoxifen, ra loxifene, and aromatase inhibition. J Clin Oncol 2002;20: 3328-43.
61. Gail MH. Personalized estimates of breast cancer risk in clinical practice and public health. Stat Med 2011;30:1090-104.
62. Cortes J, O'Shaughnessy J, Loesch D, Blum JL, Vahdat LT, Petrakova K, et al. Eribulin monotherapy versus treatmentof physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomized study. Lancet 2011;377:914-23.
63. Del Mastro L, Boni L, Michelotti A, Gamucci T, Olmeo N, Gori S, et al. Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer: a randomized trial. JAMA 2011;306:269-76.
64. Anders CK, Hsu DS, Broadwater G, Acharya CR, Foekens JA, Zhang Y, et al. Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression. J Clin Oncol 2008; 26:3324-30.
65. Gerber B, Dieterich M, Muller H, Reimer T. Controversies in preservation of ovary function and fertility in patients with breast cancer. Breast Cancer Res Treat 2008;108:1-7.
66. Ataya K, Rao LV, Lawrence E, Kimmel R. Luteinizing hormone-releasing hormone agonist inhibits cyclophos pha mide-induced ovarian follicular depletion in rhesus monkeys. Biol Reprod 1995;52:365-72.
67. Urruticoechea A, Arnedos M, Walsh G, Dowsett M, Smith IE. Ovarian protection with goserelin during adjuvant che-motherapy for pre-menopausal women with early breast cancer (EBC). Breast Cancer Res Treat 2008;110:411-6.
68. Kim SS, Lee JR, Jee BC, Suh CS, Kim SH, Ting A, et al. Use of hormonal protection for chemotherapy-induced gonado toxicity. Clin Obstet Gynecol 2010;53:740-52.